Taux d’incidence de 2012 à 2016, par groupe diagnostique et par tranche d'âge - RNCE

Registre National des Cancers de l’Enfant

Annual number of cases (N), age specific annual incidence rates (IR), mainland France 2012-2016.

               
                 
 

< 1 year

1-4 years

5-9 years

10-14 years

Diagnostic groups and subgroups

N

IR

N

IR

N

IR

N

IR

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

30

40.1

217

70.4

156

39.3

116

29.2

I.a Lymphoid leukemias

12

16.1

187

60.6

130

32.6

85

21.3

I.b Acute myeloid leukemias

12

16.1

23

7.4

19

4.7

21

5.3

II. Lymphomas and reticuloendothelial neoplasms

1

1.3

24

7.7

57

14.3

109

27.5

II.a Hodgkin lymphomas

0

0.0

3

1.0

18

4.4

73

18.4

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

1

0.8

10

3.4

19

4.8

26

6.6

II.c Burkitt lymphomas

0

0.0

10

3.4

20

5.1

10

2.5

III. CNS and miscellaneous intracranial and intraspinal neoplasms

28

37.4

157

51.0

157

39.4

138

34.9

III.a Ependymomas and choroid plexus tumors

6

7.5

22

7.0

10

2.5

7

1.9

III.b Astrocytomas

8

11.3

72

23.3

56

14.2

44

11.0

III.c Intracranial and intraspinal embryonal tumors

7

8.9

30

9.6

34

8.7

15

3.9

III.d Other gliomas

2

3.0

14

4.7

27

6.8

19

4.7

III.e Other specified intracranial and intraspinal neoplasms

4

5.9

16

5.3

27

6.8

51

13.0

IV. Neuroblastomas and other peripheral nervous cell tumors

54

72.3

65

20.9

17

4.2

5

1.2

IV.a Neuroblastomas and ganglioneuroblastomas

54

72.3

64

20.7

17

4.2

4

0.9

V. Retinoblastomas

22

29.3

27

8.8

2

0.5

0

0.1

VI. Renal tumors

13

17.7

57

18.4

20

5.0

5

1.2

VI.a Nephroblastomas and other nonepithelial renal tumors

13

17.7

57

18.4

19

4.8

3

0.8

VII. Hepatic tumors

6

7.5

10

3.1

2

0.6

2

0.6

VII.a Hepatoblastomas

5

7.3

9

2.9

2

0.6

0

0.1

VIII. Malignant bone tumors

1

1.1

6

1.9

22

5.5

62

15.5

VIII.a Osteosarcomas

0

0.0

1

0.3

9

2.3

30

7.7

VIII.c Ewing tumors and related bone sarcomas

1

0.8

4

1.4

11

2.7

28

7.1

IX. Soft tissue and other extraosseous sarcomas

12

16.4

36

11.6

30

7.5

32

8.0

IX.a Rhabdomyosarcomas

5

7.0

27

8.6

18

4.5

10

2.5

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

2

3.2

1

0.3

2

0.6

3

0.8

IX.d Other specified soft tissue sarcomas

3

4.6

7

2.1

7

1.9

15

3.8

IX.e Unspecified soft tissue sarcomas

1

1.6

2

0.5

2

0.6

4

0.9

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

12

15.9

13

4.2

12

3.0

28

7.1

X.a Intracranial and intraspinal germ cell tumors

1

1.9

5

1.6

8

2.0

13

3.2

X.b Malignant extracranial and extragonadal germ cell tumors

9

11.6

5

1.6

0

0.1

1

0.2

X.c Malignant gonadal germ cell tumors

2

2.2

3

1.0

4

1.0

13

3.2

XI. Other malignant epithelial neoplasms and malignant melanomas

2

2.4

7

2.4

13

3.3

50

12.6

XI.b Thyroid carcinomas

0

0.5

2

0.5

3

0.8

17

4.2

XI.d Malignant melanomas

0

0.0

3

0.9

3

0.7

5

1.3

XII. Other and unspecified malignant neoplasms

2

2.2

3

0.9

0

0.1

1

0.2

All cancers (excluding Langherhans cell histiocytosis)

181

243.5

622

201.3

488

122.8

547

138.0

Langherhans cell histiocytosis

2

2.2

3

1.0

0

0.1

1

0.2

All cancers (including Langherhans cell histiocytosis)

183

245.7

625

202.3

488

122.9

548

138.2

Villejuif

INSERM
UMRS1153 Equipe 7
Bâtiment 15/16
16 avenue Paul Vaillant Couturier
94807 Villejuif Cedex

+33 (0)1 45 59 50 37
rnhe@inserm.fr

Nancy

Faculté de Médecine
BP 20199
9 avenue de la Forêt de Haye
54505 Vandoeuvre les Nancy Cedex

+33 (0)3 72 74 63 26
rntse@inserm.fr